Eli Lilly and Company (NYSE: LLY) disclosed that the US government has informed the firm that authorities will buy at least 100,000 doses of bamlanivimab 700 mg and etesevimab 1400 mg together. The combined doses of bamlanivimab and etesevimab have recently got the EUA for the cure of sufferers experiencing COVID-19.
Furthermore, NIH had recently upgraded the COVID-19 Treatment Guidelines to suggest the use of bamlanivimab plus etesevimab for the cure of sufferers with minor to moderate COVID-19 who are at high risk of clinical development. The US authorities will purchase the doses for $210 million and the firm is preparing to supply till March 31, 2021.
As per the agreement, US authorities have also the opportunity to purchase up to extra 1,100,000 doses through November 25, 2021. The new option will be provided to the US authorities under the same terms as the base deal and dependent on the deal with Lilly, product availability, and the medical need in the U.S.
This buying complements the delivery of neutralizing antibodies already accessible for use in the U.S. The authorities have pledged to buy a total of 1,450,000 doses of bamlanivimab alone, which includes more than 1 million doses that have been shipped and a deal to supply 450,000 extra doses by March 31, 2021. The authorities have said it will offer neutralizing antibodies at no out-of-pocket cost to sufferers, although healthcare services may charge a fee for the product's inoculation.